Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Is Snapdeal’s New Approach Reaping Rewards?

By Jagat Joshi
December 10, 2021

Snapdeal’s IPO is coming out early next year and the news has surprised many metro dwelling folks as they haven’t heard much about Snapdeal in the last few years. It has been mostly out of sight and out of mind for most people.

So over to the moot question; what has Snapdeal been up to that is leading up to the IPO news?

Well, before you decide this way or the other it’s useful to understand Snapdeal’s journey in the last 4-5 years and how their business is panning out. Some people in the know of things are aware that Snapdeal has been working under the hood with very different approaches and has silently staged a comeback in the value e-commerce space. Let’s find out a bit more about this journey.

Snapdeal: The Pioneer of Indian E-commerce

A bit of history first to understand the pedigree of the company and its management. Co-founded in February 2010, by Kunal Bahl and Rohit Bansal, Snapdeal is the Pioneer of Indian E-commerce. It was one of India’s earliest Unicorns. Within six years, it achieved a market valuation of $6.5 billion and became the second-biggest e-commerce company in the country (source: Forbes India). However, other big players like Flipkart, Amazon eventually took large market shares in the market denting Snapdeal. Many thought it was the end of the road for Snapdeal but the founders had other plans.

They embarked on a new path to rebuilding Snapdeal. With a bigger responsibility to re-establish Snapdeal in the market, the co-founders came up with a new approach, a move that would eventually change the fortunes of Snapdeal.

The new approach:

A fresh approach needed a fresh evaluation of the current business environment and the Snapdeal founders were quick to assess the massive growth in internet penetration being expedited by the entry of Jio.

The JIO Internet Revolution:

In 2016, Jio completely revolutionized the use of the Internet in India. Now everyone had access to the Internet in the country, which led to the growth of a new wave of consumerism in India – Bharat.
Bharat comprises the aspirations of people of tier 2-4 cities and rural areas. As they hooked on to the internet, they started changing their lifestyle to what’s the latest but with a value-conscious approach. And this led to the emergence of Value E-commerce. Let’s deep dive.

Value E-commerce:

Value E-commerce is all about providing good quality products at affordable prices to customers online. It is a segment of E-commerce that offers Value-based products instead of brand-oriented products. Functionality is given more importance than brands. As per a recent report by AT Kearney; it is the fastest-growing segment of E-commerce. And with its focused approach, Snapdeal dove deep into this segment to grab this opportunity and became a completely value E-commerce focused platform.

Shifting the Customer Base to Bharat Consumers:

Since Value E-commerce had a specific kind of Value conscious buyers, the shift to Value E-commerce meant shifting to a new customer base. These value-conscious buyers were majorly from tier 2-4 cities or rural areas, who together make the Bharat segment pegged at $90 Bn in buying potential. And this consumer base of Bharat is the target base for Snapdeal, refining its focus completely towards the tier 2+ cities and rural areas. The buyers of this segment are not brand-oriented. They go for value for money products, which offer quality, durability, and trendiness at affordable prices. Therefore Snapdeal needed a new business mindset to crack this market. Here is how they did it. – Source: YourStory

The Major Pillars of Snapdeal 2.0’s Business Model Are:

Sharp Understanding of Bharat: Snapdeal very well understands the needs of the value-conscious buyers of Bharat. Hence, Snapdeal provides good quality products at affordable prices and works closely with sellers to deliver a consistent product experience. Keeping in mind the budgets of Bharat customers, Snapdeal has priced ~95% of the products below Rs. 1000.
UniMove: UniMove is Snapdeal’s innovative logistics platform which uses AI-based software to deliver products from seller to the customer. In this, Snapdeal uses 3rd party logistics (3PL) delivery arrangement. Snapdeal uses three different delivery partners for each three steps of delivery, unlike other e-commerce players who use only one delivery partner for the whole shipment. Through UniMove, Snapdeal is able to deliver 96% pin codes in India, one of the very few brands to do so.
In-house Power brands: Power Brands are Snapdeal’s own built brands, through which Snapdeal provides good quality products at affordable prices to its customers. Snapdeal has built more than 10 Power brands across popular categories like apparel, fashion accessories, footwear. Through Power Brands, Snapdeal can closely control the quality, price, style, and packaging by working collaboratively with the seller.
Cost Management: Snapdeal has worked smartly to simplify its operations that is more suited to India and in such a way that it can be handled by a lean team structure of 650-700 people. Snapdeal doesn’t hold stock of any product (zero inventory). All the stocks remain with the seller, and products are delivered directly to customers from sellers as per the order. They also do not take any loans or debts from the market. They always make a profit on every product by selling at a higher price than the seller (positive unit economics business model). They don’t hold many physical assets like buildings, equipment, etc., neither they spend much on these (Zero Capex and Asset light Operations). They operate by taking them on lease and spending a minimal amount on them.

Result:

So did the new approach work for Snapdeal? Well, the answer is yes. With the new Business Strategy based on Value E-commerce, things finally started going well for the homegrown E-retailer. The results were even visible in Snapdeal’s financial metrics as well. Within three years, Snapdeal reduced its loss by a staggering 95%. And to add to this, it posted revenue growth of 85% from operations. Even the traffic on the platform saw a rise of 100 percent. The pandemic saw another six million users added to the customer base. More than 20,000 new sellers joined the pool of already-existing 500,000 sellers in the platform during this period. (source: Forbes India)

Current Status: Leader of Value E-commerce

While its major rivals were busy focusing on brand-oriented business, Snapdeal completely focused on Value E-commerce. And has hence become the biggest online retailer to serve the consumers of Bharat, making it the leader of Value E-commerce.

What’s next:

Future Scope of Value E-commerce:

Value E-commerce is now the fastest-growing segment of E-commerce. As per the report of Kearney, the value lifestyle retail market catering to this segment is expected to grow from $90 Bn in 2019 to $215 Bn by 2030. 19% of value buyers will be served online via value e-commerce by 2030, a huge rise from 4% in 2019. This growing number of value-conscious online buyers is giving a big boost to India’s e-commerce and is reshaping it. The Value of e-commerce, which has a current value of $4 BN, is expected to reach $40 Bn by 2030.

IPO:

SoftBank-backed Snapdeal is said to be in preparation for an IPO. As per a report by Mint, Snapdeal plans to file for an initial public offer (Snapdeal IPO). With the newfound success through the new Business Model, Snapdeal has scripted a great comeback and is reaping the rewards of the new approach. The move is paying off. And now it would be interesting to see how its upcoming IPO pans out in the market. So let’s wait and watch for Snapdeal’s DRHP to know more about this exciting company.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.